Listen to the Episode Below (00:38:42)
546: When Speed to Market Matters Most | Richard Steinhart, CFO, BioXcel Therapeutics
When asked what sets BioXcel Therapeutics apart from other clinical-stage biopharmaceutical companies, CFO Richard Steinhart doesn’t mention a specific drug or therapy. Instead, he describes a system that the company developed to advance the speed with which drugs are commercialized. According to Steinhart, the biotech company’s system uses artificial intelligence to reveal “hidden connections” that,…